Search

Your search keyword '"Casu, D."' showing total 17 results
Start Over Author "Casu, D." Search Limiters Full Text
17 results on '"Casu, D."'

1. Cancer diagnosis and suicide outcomes: prevalence and risk meta-analysis

Author

Peviani, G, Casu, D, Mansi, W, De Prisco, M, Madeddu, F, López-Castroman, J, Fornaro, M, Calati, R, Peviani G, Casu D, Mansi W, De Prisco M, Madeddu F, López-Castroman J, Fornaro M, Calati R, Peviani, G, Casu, D, Mansi, W, De Prisco, M, Madeddu, F, López-Castroman, J, Fornaro, M, Calati, R, Peviani G, Casu D, Mansi W, De Prisco M, Madeddu F, López-Castroman J, Fornaro M, and Calati R

Published
2022

2. Cancer diagnosis and suicide outcomes: Umbrella review and methodological considerations

Author

Calati, R, Filipponi, C, Mansi, W, Casu, D, Peviani, G, Gentile, G, Tambuzzi, S, Zoja, R, Fornaro, M, Lopez-Castroman, J, Madeddu, F, Calati R., Filipponi C., Mansi W., Casu D., Peviani G., Gentile G., Tambuzzi S., Zoja R., Fornaro M., Lopez-Castroman J., Madeddu F., Calati, R, Filipponi, C, Mansi, W, Casu, D, Peviani, G, Gentile, G, Tambuzzi, S, Zoja, R, Fornaro, M, Lopez-Castroman, J, Madeddu, F, Calati R., Filipponi C., Mansi W., Casu D., Peviani G., Gentile G., Tambuzzi S., Zoja R., Fornaro M., Lopez-Castroman J., and Madeddu F.

Abstract

Background: Suicide outcomes in cancer patients represent a major public health concern. We performed an umbrella review (UR) including all meta-analyses (MAs) and systematic reviews (SRs) published on the association between cancer and suicide outcomes. Methods: Eligible studies were searched in the main scientific databases up to January 23rd, 2021. Eligible MAs/SRs focused on all suicide phenotypes among cancer patients. Evidence of the association was extracted; the credibility and quality of the included studies were evaluated using ad-hoc tools, including “A MeaSurement Tool to Assess systematic Reviews-2-Revised” (AMSTAR-2-R). Results: Six MAs and 6 SRs were included. The standardized mortality ratio of suicide in cancer patients was 1.5 to 1.7-fold higher than in the general population. Risk factors for suicide outcomes among cancer patients were male sex and older age, a cancer diagnosis within the prior year, and some specific cancer sites. Among 107 associations, 90 (84.1%) were supported by high credibility of evidence (class II). However, all studies reported a large heterogeneity (I2> 50%) and the majority of them reported considerable heterogeneity (I2> 75%). All MAs used random-effects measures. All MAs but one assessed publication bias and only one disclosed it. The majority of MAs/SRs showed critically low quality based on AMSTAR-2-R. Limitations: We could not perform additional analyses due to the limited number of MAs. Conclusions: This UR underlines the inflated risk for suicide among cancer patients. Upcoming, well-designed studies are needed to account for a broader set of variables. Several methodological issues likewise warrant attention.

Published
2021

3. Cancer diagnosis and suicide outcomes: prevalence and risk meta-analysis

Author

Peviani G, Casu D, Mansi W, De Prisco M, Madeddu F, López-Castroman J, Fornaro M, Calati R, Peviani, G, Casu, D, Mansi, W, De Prisco, M, Madeddu, F, López-Castroman, J, Fornaro, M, and Calati, R

Subjects
Psychiatry and Mental health, Cancer, suicide, meta-analysis
Abstract

Introduction Available meta-analytic evidence suggests an increased risk of suicide among cancer patients, although most of the reports focused on the sole suicide death (SD) outcome and they are usually hampered by significant between-study heterogeneity. Objectives The present meta-analysis aimed at assessing the prevalence and risk rates of SD, suicide attempt (SA), and suicidal ideation (SI) among cancer patients. Methods Systematic search up to April 2021 of observational studies documenting cancer and suicide outcomes associations. Pooled prevalence estimates, odd ratios (ORs), risk ratios (RRs), and hazard ratios (HRs) of SD, SA, and SI were computed according to the random-effects model. SD prevalence underwent cumulative and sub-group analyses for different variables. Risk estimates underwent sensitivity analysis for study design. Results Overall, thirty-nine studies were included. A higher risk of SD based on HR, SA based on OR and HR, and SI based on each measure was recorded among cancer patients versus controls. OR and RR of SD were not significant. Pooled prevalence rates of SD, SA and SI among cancer patients were 1.9% (1.1-3.1%), 1.4% (0.3-7.1%), and 9.1% (5.8-14.0%), respectively. Although high between-study heterogeneity held upon sensitivity and sub-group analyses, the overall message brought by risk analyses likewise held true. Age, country, study design, cancer type, sample size, cases type and comparison affected SD prevalence estimates in cancer patients. SD prevalence decreased over time. Conclusions Cancer patients face higher risk for SA and SI versus controls. SD’ results were controversial. Cancer patients have higher prevalence rates of suicide outcomes compared to the general population. Disclosure No significant relationships.

Published
2022
Full Text
View/download PDF

4. Mutations in DSTYK and dominant urinary tract malformations

Author

Sanna Cherchi, S, Sampogna, Rv, Papeta, N, Burgess, Ke, Nees, Sn, Perry, Bj, Choi, M, Bodria, M, Liu, Y, Weng, Pl, Lozanovski, Vj, Verbitsky, M, Lugani, F, Sterken, R, Paragas, N, Caridi, G, Carrea, A, Dagnino, M, Materna Kiryluk, A, Santamaria, G, Murtas, C, Ristoska Bojkovska, N, Izzi, C, Kacak, N, Bianco, B, Giberti, S, Gigante, M, Piaggio, G, Gesualdo, L, Kosuljandic Vukic, D, Vukojevic, K, Saraga Babic, M, Saraga, M, Gucev, Z, Allegri, L, Latos Bielenska, A, Casu, D, State, M, Scolari, F, Ravazzolo, Roberto, Kiryluk, K, Al Awqati, Q, D'Agati, Vd, Drummond, Ia, Tasic, V, Lifton, Rp, Ghiggeri, Gm, and Gharavi, Ag

Subjects
Male, Kidney Disease, Genetic Linkage, 030232 urology & nephrology, Genome-wide association study, Bioinformatics, medicine.disease_cause, Fibroblast growth factor, Kidney, Medical and Health Sciences, Mice, 0302 clinical medicine, 2.1 Biological and endogenous factors, Exome, RNA, Small Interfering, Aetiology, Urinary Tract, Child, Pediatric, 0303 health sciences, Mutation, General Medicine, 3. Good health, Pedigree, medicine.anatomical_structure, Receptor-Interacting Protein Serine-Threonine Kinases, Gene Knockdown Techniques, Female, Biotechnology, Adult, Urologic Diseases, Heterozygote, Urinary system, 1.1 Normal biological development and functioning, Molecular Sequence Data, Renal and urogenital, Small Interfering, 03 medical and health sciences, Young Adult, Clinical Research, Underpinning research, General & Internal Medicine, medicine, Genetics, Animals, Humans, 030304 developmental biology, Base Sequence, business.industry, Human Genome, Infant, Heterozygote advantage, Urogenital Abnormalities, Etiology, RNA, Congenital Structural Anomalies, business, Genome-Wide Association Study
Abstract

BackgroundCongenital abnormalities of the kidney and the urinary tract are the most common cause of pediatric kidney failure. These disorders are highly heterogeneous, and the etiologic factors are poorly understood.MethodsWe performed genomewide linkage analysis and whole-exome sequencing in a family with an autosomal dominant form of congenital abnormalities of the kidney or urinary tract (seven affected family members). We also performed a sequence analysis in 311 unrelated patients, as well as histologic and functional studies.ResultsLinkage analysis identified five regions of the genome that were shared among all affected family members. Exome sequencing identified a single, rare, deleterious variant within these linkage intervals, a heterozygous splice-site mutation in the dual serine-threonine and tyrosine protein kinase gene (DSTYK). This variant, which resulted in aberrant splicing of messenger RNA, was present in all affected family members. Additional, independent DSTYK mutations, including nonsense and splice-site mutations, were detected in 7 of 311 unrelated patients. DSTYK is highly expressed in the maturing epithelia of all major organs, localizing to cell membranes. Knockdown in zebrafish resulted in developmental defects in multiple organs, which suggested loss of fibroblast growth factor (FGF) signaling. Consistent with this finding is the observation that DSTYK colocalizes with FGF receptors in the ureteric bud and metanephric mesenchyme. DSTYK knockdown in human embryonic kidney cells inhibited FGF-stimulated phosphorylation of extracellular-signal-regulated kinase (ERK), the principal signal downstream of receptor tyrosine kinases.ConclusionsWe detected independent DSTYK mutations in 2.3% of patients with congenital abnormalities of the kidney or urinary tract, a finding that suggests that DSTYK is a major determinant of human urinary tract development, downstream of FGF signaling. (Funded by the National Institutes of Health and others.).

Published
2013

5. Phosphate levels in patients treated with low-flux haemodialysis, pre-dilution haemofiltration and haemodiafiltration: post hoc analysis of a multicentre, randomized and controlled trial

Author

Locatelli, F., primary, Altieri, P., additional, Andrulli, S., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Gazzanelli, L., additional, Tampieri, G., additional, Isola, E., additional, Marzolla, O., additional, Memoli, B., additional, Ganadu, M., additional, Reina, E., additional, Bertoli, S., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Mattana, G., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, Di Iorio, B. R., additional, Pontoriero, G., additional, and Zoccali, C., additional

Published
2014
Full Text
View/download PDF

6. I Policheti meiobentonici delle Secche della Meloria

Author

Casu, D., Milella, I., Castelli, A., and Todaro, Mary Antonio Donatello

Subjects
annelida, Policheti, invertebrati, benthos, mediterraneo, Meloria, meiofauna, fauna italiana, zoologia
Published
2000

7. Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial

Author

Locatelli, F., primary, Altieri, P., additional, Andrulli, S., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Feriani, M., additional, Nebiolo, P. E., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Cadinu, F., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, Di Iorio, B. R., additional, and Zoccali, C., additional

Published
2012
Full Text
View/download PDF

8. Extracorporeal dialysis: techniques and adequacy

Author

Donadio, C., primary, Kanaki, A., additional, Martin-Gomez, A., additional, Garcia, S., additional, Palacios-Gomez, M., additional, Donadio, C., additional, Calia, D., additional, Colombini, E., additional, DI Francesco, F., additional, Ghimenti, S., additional, Onor, M., additional, Tognotti, D., additional, Fuoco, R., additional, Marka-Castro, E., additional, Torres Zamora, M. I., additional, Giron-Mino, J., additional, Jaime-Solis, M. A., additional, Arteaga, L. M., additional, Romero, H., additional, Akonur, A., additional, Leypoldt, K., additional, Asola, M., additional, Culleton, B., additional, Eloot, S., additional, Glorieux, G., additional, Nathalie, N., additional, Vanholder, R., additional, Perez de Jose, A., additional, Verdalles Guzman, U., additional, Abad Esttebanez, S., additional, Vega Martinez, A., additional, Barraca, D., additional, Yuste, C., additional, Bucalo, L., additional, Rincon, A., additional, Lopez-Gomez, J. M., additional, Bataille, P., additional, Celine, P., additional, Raymond, A., additional, Francois, G., additional, Herve, L., additional, Michel, D., additional, Jean Louis, R., additional, Zhu, F., additional, Kotanko, P., additional, Thijssen, S., additional, Levin, N. W., additional, Papamichail, N., additional, Bougiakli, M., additional, Gouva, C., additional, Antoniou, S., additional, Gianitsi, S., additional, Vlachopanou, A., additional, Chachalos, S., additional, Naka, K., additional, Kaarsavvidou, D., additional, Katopodis, K., additional, Michalis, L., additional, Sasaki, K., additional, Yasuda, K., additional, Yamato, M., additional, Surace, A., additional, Rovatti, P., additional, Steckiph, D., additional, Bandini, R., additional, Severi, S., additional, Dellacasa Bellingegni, A., additional, Santoro, A., additional, Arias, M., additional, Sentis, A., additional, Perez, N., additional, Fontsere, N., additional, Vera, M., additional, Rodriguez, N., additional, Arcal, C., additional, Ortega, N., additional, Uriza, F., additional, Cases, A., additional, Maduell, F., additional, Abbas, S. R., additional, Georgianos, P., additional, Sarafidis, P., additional, Nikolaidis, P., additional, Lasaridis, A., additional, Ahmed, A., additional, Kaoutar, H., additional, Mohammed, B., additional, Zouhir, O., additional, Balter, P., additional, Ginsberg, N., additional, Taylor, P., additional, Sullivan, T., additional, Usvyat, L. A., additional, Zabetakis, P., additional, Moissl, U., additional, Ferrario, M., additional, Garzotto, F., additional, Wabel, P., additional, Cruz, D., additional, Tetta, C., additional, Signorini, M. G., additional, Cerutti, S., additional, Brendolan, A., additional, Ronco, C., additional, Heaf, J., additional, Axelsen, M., additional, Pedersen, R. S., additional, Amine, H., additional, Oualim, Z., additional, Ammirati, A. L., additional, Guimaraes de Souza, N. K., additional, Nemoto Matsui, T., additional, Luiz Vieira, M., additional, Alves de Oliveira, W. A., additional, Fischer, C. H., additional, Dias Carneiro, F., additional, Iizuka, I. J., additional, Aparecida de Souza, M., additional, Mallet, A. C., additional, Cruz Andreoli, M. C., additional, Cardoso Dos Santos, B. F., additional, Rosales, L., additional, Dou, Y., additional, Carter, M., additional, Testa, A., additional, Sottini, L., additional, Giacon, B., additional, Prati, E., additional, Loschiavo, C., additional, Brognoli, M., additional, Marseglia, C., additional, Tommasi, A., additional, Sereni, L., additional, Palladino, G., additional, Bove, S., additional, Bosticardo, G., additional, Schillaci, E., additional, Detoma, P., additional, Bergia, R., additional, Park, J. W., additional, Moon, S. J., additional, Choi, H. Y., additional, Ha, S. K., additional, Park, H.-C., additional, Liao, Y., additional, Zhang, L., additional, Fu, P., additional, Igarashi, H., additional, Suzuki, N., additional, Esashi, S., additional, Masakane, I., additional, Panichi, V., additional, De Ferrari, G., additional, Saffiotti, S., additional, Sidoti, A., additional, Biagioli, M., additional, Bianchi, S., additional, Imperiali, P., additional, Gabrielli, C., additional, Conti, P., additional, Patrone, P., additional, Rombola, G., additional, Falqui, V., additional, Mura, C., additional, Icardi, A., additional, Rosati, A., additional, Santori, F., additional, Mannarino, A., additional, Bertucci, A., additional, Jeong, J., additional, Kim, O. K., additional, Kim, N. H., additional, Bots, M., additional, Den Hoedt, C., additional, Grooteman, M. P., additional, Van der Weerd, N. C., additional, Mazairac, A. H. A., additional, Levesque, R., additional, Ter Wee, P. M., additional, Nube, M. J., additional, Blankestijn, P., additional, Van den Dorpel, M. A., additional, Park, Y., additional, Jeon, J., additional, Tessitore, N., additional, Bedogna, V., additional, Girelli, D., additional, Corazza, L., additional, Jacky, P., additional, Guillaume, Q., additional, Julien, B., additional, Marcinkowski, W., additional, Drozdz, M., additional, Milkowski, A., additional, Rydzynska, T., additional, Prystacki, T., additional, August, R., additional, Benedyk-Lorens, E., additional, Bladek, K., additional, Cina, J., additional, Janiszewska, G., additional, Kaczmarek, A., additional, Lewinska, T., additional, Mendel, M., additional, Paszkot, M., additional, Trafidlo, E., additional, Trzciniecka-Kloczkowska, M., additional, Vasilevsky, A., additional, Konoplev, G., additional, Lopatenko, O., additional, Komashnya, A., additional, Visnevsky, K., additional, Gerasimchuk, R., additional, Neivelt, I., additional, Frorip, A., additional, Vostry, M., additional, Racek, J., additional, Rajdl, D., additional, Eiselt, J., additional, Malanova, L., additional, Pechter, U., additional, Selart, A., additional, Ots-Rosenberg, M., additional, Krieter, D. H., additional, Seidel, S., additional, Merget, K., additional, Lemke, H.-D., additional, Wanner, C., additional, Canaud, B., additional, Rodriguez, A., additional, Morgenroth, A., additional, Von Appen, K., additional, Dragoun, G.-P., additional, Fluck, R., additional, Fouque, D., additional, Lockridge, R., additional, Motomiya, Y., additional, Uji, Y., additional, Hiramatsu, T., additional, Ando, Y., additional, Furuta, M., additional, Kuragano, T., additional, Kida, A., additional, Yahiro, M., additional, Otaki, Y., additional, Hasuike, Y., additional, Nonoguchi, H., additional, Nakanishi, T., additional, Sain, M., additional, Kovacic, V., additional, Ljutic, D., additional, Radic, J., additional, Jelicic, I., additional, Yalin, S. F., additional, Trabulus, S., additional, Yalin, A. S., additional, Altiparmak, M. R., additional, Serdengecti, K., additional, Ohtsuka, A., additional, Fukami, K., additional, Ishikawa, K., additional, Ando, R., additional, Kaida, Y., additional, Adachi, T., additional, Sugi, K., additional, Okuda, S., additional, Nesterova, O. B., additional, Suglobova, E. D., additional, Golubev, R. V., additional, Vasiliev, A. N., additional, Lazeba, V. A., additional, Smirnov, A. V., additional, Arita, K., additional, Kihara, E., additional, Maeda, K., additional, Oda, H., additional, Doi, S., additional, Masaki, T., additional, Hidaka, S., additional, Ishioka, K., additional, Oka, M., additional, Moriya, H., additional, Ohtake, T., additional, Nomura, S., additional, Kobayashi, S., additional, Wagner, S., additional, Gmerek, A., additional, Wagner, J., additional, Wizemann, V., additional, Eftimovska - Otovic, N., additional, Spaseska-Gjurovska, K., additional, Bogdanovska, S., additional, Babalj - Banskolieva, E., additional, Milovanceva, M., additional, Grozdanovski, R., additional, Pisani, A., additional, Riccio, E., additional, Mancini, A., additional, Ambuhl, P., additional, Astrid, S., additional, Ivana, P., additional, Martin, H., additional, Thomas, K., additional, Hans-Rudolf, R., additional, Daniel, A., additional, Denes, K., additional, Marco, M., additional, Wuthrich, R. P., additional, Andreas, S., additional, Andrulli, S., additional, Altieri, P., additional, Sau, G., additional, Bolasco, P., additional, Pedrini, L. A., additional, Basile, C., additional, David, S., additional, Feriani, M., additional, Nebiolo, P. E., additional, Ferrara, R., additional, Casu, D., additional, Logias, F., additional, Tarchini, R., additional, Cadinu, F., additional, Passaghe, M., additional, Fundoni, G., additional, Villa, G., additional, DI Iorio, B. R., additional, Zoccali, C., additional, Locatelli, F., additional, Hamamoto, M., additional, Lee, D.-Y., additional, Kim, B., additional, Moon, K. H., additional, LI, Z., additional, Ahrenholz, P., additional, Winkler, R. E., additional, Waitz, G., additional, Wolf, H., additional, Grundstrom, G., additional, Alquist, M., additional, Holmquist, M., additional, Christensson, A., additional, Bjork, P., additional, Abdgawad, M., additional, Ekholm, L., additional, Segelmark, M., additional, Corsi, C., additional, De Bie, J., additional, Mambelli, E., additional, Mortara, D., additional, Arroyo, D., additional, Panizo, N., additional, Quiroga, B., additional, Reque, J., additional, Melero, R., additional, Rodriguez-Ferrero, M., additional, Rodriguez-Benitez, P., additional, Anaya, F., additional, Luno, J., additional, Ragon, A., additional, James, A., additional, Brunet, P., additional, Ribeiro, S., additional, Faria, M. S., additional, Rocha, S., additional, Rodrigues, S., additional, Catarino, C., additional, Reis, F., additional, Nascimento, H., additional, Fernandes, J., additional, Miranda, V., additional, Quintanilha, A., additional, Belo, L., additional, Costa, E., additional, Santos-Silva, A., additional, Arund, J., additional, Tanner, R., additional, Fridolin, I., additional, Luman, M., additional, Clajus, C., additional, Kielstein, J. T., additional, Haller, H., additional, Libutti, P., additional, Lisi, P., additional, Vernaglione, L., additional, Casucci, F., additional, Losurdo, N., additional, Teutonico, A., additional, Lomonte, C., additional, Krisp, C., additional, Wolters, D. A., additional, Matsuyama, M., additional, Tomo, T., additional, Ishida, K., additional, Matsuyama, K., additional, Nakata, T., additional, Kadota, J., additional, Caiazzo, M., additional, Monari, E., additional, Cuoghi, A., additional, Bellei, E., additional, Bergamini, S., additional, Tomasi, A., additional, Baranger, T., additional, Seniuta, P., additional, Berge, F., additional, Drouillat, V., additional, Frangie, C., additional, Rosier, E., additional, Labonia, W., additional, Lescano, A., additional, Rubio, D., additional, Von der Lippe, N., additional, Jorgensen, J. A., additional, Osthus, T. B., additional, Waldum, B., additional, Os, I., additional, Bossola, M., additional, DI Stasio, E., additional, Antocicco, M., additional, Tazza, L., additional, Griveas, I., additional, Karameris, A., additional, Pasadakis, P., additional, Savica, V., additional, Santoro, D., additional, Saitta, S., additional, Tigano, V., additional, Bellinghieri, G., additional, Gangemi, S., additional, Daniela, R., additional, Checherita, I. A., additional, Ciocalteu, A., additional, Vacaroiu, I. A., additional, Niculae, A., additional, Stefaniak, E., additional, Pietrzak, I., additional, Krupa, D., additional, Garred, L., additional, Mancini, E., additional, Corrazza, L., additional, Atti, M., additional, Afsar, B., additional, Stamopoulos, D., additional, Mpakirtzi, N., additional, Gogola, B., additional, Zeibekis, M., additional, Stivarou, D., additional, Panagiotou, M., additional, Grapsa, E., additional, Vega Vega, O., additional, Barraca Nunez, D., additional, Fernandez-Lucas, M., additional, Gomis, A., additional, Teruel, J. L., additional, Elias, S., additional, Quereda, C., additional, Hignell, L., additional, Humphrey, S., additional, Pacy, N., additional, and Afentakis, N., additional

Published
2012
Full Text
View/download PDF

9. Identification of a new mutation in the alpha4(IV) collagen gene in a family with autosomal dominant Alport syndrome and hypercholesterolaemia.

Author

Ciccarese, M, Casu, D, Ki Wong, F, Faedda, R, Arvidsson, S, Tonolo, G, Luthman, H, and Satta, A

Abstract

Alport syndrome (AS) is a hereditary disease of the glomerular basement membrane in the kidney characterized by progressive renal failure, sensorineural deafness, and/or ocular abnormalities. In contrast to the well-known X-linked phenotype, very little is known about the autosomal dominant form. Rare autosomal forms of AS have been described with mutations in COL4A3 and COL4A4 at chromosome region 2q35-q37, but there have been no descriptions of dominant forms due to a mutation in COL4A4.

Published
2001
Full Text
View/download PDF

10. Predilution haemofiltration--the Second Sardinian Multicentre Study: comparisons between haemofiltration and haemodialysis during identical Kt/V and session times in a long-term cross-over study.

Author

Altieri, P, Sorba, G, Bolasco, P, Asproni, E, Ledebo, I, Cossu, M, Ferrara, R, Ganadu, M, Cadinu, F, Serra, G, Cabiddu, G, Sau, G, Casu, D, Passaghe, M, Bolasco, F, Pistis, R, and Ghisu, T

Abstract

The potential superiority of various renal replacement treatment modalities consisting largely of convective mass transfer as opposed to primarily diffusive mass transfer, is still a matter of debate. The objective of the present study was to evaluate acute and long-term clinical effects of varying degrees of convection and diffusion in a group of 24 clinically stable patients with end-stage renal disease.

Published
2001
Full Text
View/download PDF

12. [Effects of Dose of Erythropoiesis Stimulating Agents on Cardiovascular Outcomes, Quality of Life and Costs of Haemodialysis. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) Trial]

Author

Saglimbene V, D'Alonzo D, Ruospo M, Vecchio M, Natale P, Gargano L, Nicolucci A, Pellegrini F, Jc, Craig, Triolo G, Da, Procaccini, Santoro A, Giulio S, Rosa S, Murgo A, Mammarella R, Sambati M, D'Ambrosio N, Greco V, Giannoccaro G, Flammini A, Boccia E, Montalto G, Pagano S, Amarù S, Fici M, Lumaga G, Mancini E, Veronesi M, Patregnani L, Querques M, Schiavone P, Chimienti S, Palumbo R, Franco D, Volpe M, Gori E, Salomone M, Iacono A, Moscoloni M, Treglia A, Casu D, Am, Piras, Silva A, Mandreoli M, Lopez A, Quarello F, Catizone L, Russo G, Forcellini S, Maccarone M, Catucci G, Paolo B, Stingone A, D'Angelo B, Guastoni C, Pasquali S, Minoretti C, Bellasi A, Boscutti G, Martone M, David S, Schito F, Urban L, Iorio B, Caruso F, Mazzoni A, Musacchio R, Andreoli D, Cossu M, Cavoli G, Cornacchiari M, Granata A, Clementi A, Giordano R, Barzaghi W, Miriam Valentini, Hegbrant J, Tognoni G, and Gf, Strippoli

Subjects
Risk, Dose-Response Relationship, Drug, Disease Management, Anemia, Middle Aged, Hemoglobins, Observational Studies as Topic, Double-Blind Method, Meta-Analysis as Topic, Renal Dialysis, Research Design, Outcome Assessment, Health Care, Hematinics, Quality of Life, Humans, Kidney Failure, Chronic, Diabetic Nephropathies, Female
Abstract

Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are the most used treatment option. In observational studies, higher haemoglobin (Hb) levels (around 11-13 g/dL) are associated with improved survival and quality of life compared to Hb levels around 9-10 g/dL. Randomized studies found that targeting higher Hb levels with ESA causes an increased risk of death, mainly due to adverse cardiovascular outcomes. It is possible that this is mediated by ESA dose rather than haemoglobin concentration, although this hypothesis has never been formally tested.We present the protocol of the Clinical Evaluation of the Dose of Erythropoietins (C.E. DOSE) trial, which will assess the benefits and harms of a high versus a low ESA dose therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD). This is a randomized, prospective open label blinded end-point (PROBE) design trial due to enroll 900 haemodialysis patients. Patients will be randomized 1:1 to 4000 UI/week i. v. versus 18000 UI/week i. v. of epoetin alfa, beta or any other epoetin in equivalent doses. The primary outcome of the trial is a composite of cardiovascular events. In addition, quality of life and costs of these two strategies will be assessed. The study has been approved and funded by the Italian Agency of Drugs (Agenzia Italiana del Farmaco (AIFA)) within the 2006 funding plan for independent research on drugs (registered at www.clinicaltrials.gov (NCT00827021)).

14. Vitamins (A, C and E) and oxidative status of hemodialysis patients treated with HFR and HFR-Supra.

Author

Palleschi S, Ghezzi PM, Palladino G, Rossi B, Ganadu M, Casu D, Cossu M, Mattana G, Pinna AM, Contu B, Ghisu T, Monni A, Gazzanelli L, Mereu MC, Logias F, Passaghe M, Amore A, and Bolasco P

Subjects
Adult, Advanced Oxidation Protein Products blood, Aged, Aged, 80 and over, Cross-Over Studies, Female, Humans, Lipids blood, Male, Middle Aged, Oxidative Stress, Prospective Studies, Retinol-Binding Proteins, Plasma metabolism, Young Adult, Antioxidants metabolism, Ascorbic Acid blood, Hemodiafiltration methods, Kidney Failure, Chronic therapy, Vitamin A blood, Vitamin E blood
Abstract

Background: Hemodiafiltration with on-line endogenous reinfusion (HFR) is an extracorporeal dialytic method that combines diffusion, convection and adsorption. HFR-Supra (HFR-S) is a second-generation system with increased convective permeability and adsorption capability. Previous studies suggested that HFR reduces oxidative stress compared to standard haemodialysis. The principal aim of the present study was to compare antioxidant vitamins behavior and oxidative status of hemodialysis patients treated with HFR and HFR-S., Methods: The study was designed as a multicenter, randomized, crossover trial. Forty-one patients were recruited from 19 dialysis centers and after a 4-month washout stabilization period in on-line hemodiafiltration (ol-HDF), each patient was randomized to a sequence of treatments (HFR-S followed by HFR or viceversa) with each treatment applied over 6 months. Plasma levels of Advanced Oxidation Protein Products, Total Antioxidant Status, vitamins C, A and E and their ligands (Retinol Binding Protein and total lipids) were measured at baseline and at the end of each treatment period., Results: Results show that the higher convective permeability of HFR-S with respect to HFR did not produce additional beneficial effects on the patients' oxidative status, a slight decrease of both Vitamin A and Retinol Binding Protein being the only difference registered in the long-term. However, as compared to ol-HDF, both the re-infusive techniques allowed to reduce the intradialytic loss of Vitamin C and, in the long-term, improve the patients' oxidative status and increase Retinol Binding Protein plasma values. No significant differences were found between the Vitamin C concentration of pre- and post cartridge UF neither in HFR-S nor in HFR showing that the sorbent resin does not adsorb Vitamin C., Conclusion: HFR-S and HFR are almost equivalent in term of impact on antioxidant vitamins and oxidative status of hemodialysis patients. Nonetheless, as compared to ol-HDF, both treatments produced a sensible sparing of Vitamin C and may represent a new approach for reducing oxidative stress and related complications in dialysis patients. Long-term effects of re-infusive treatments on patients' cardiovascular morbidity and mortality need to be evaluated., Trial Registration: ClinicalTrials.gov Identifier NCT01492491 , retrospectively registered in 10 December 2011.

Published
2016
Full Text
View/download PDF

15. Localization of a gene for nonsyndromic renal hypodysplasia to chromosome 1p32-33.

Author

Sanna-Cherchi S, Caridi G, Weng PL, Dagnino M, Seri M, Konka A, Somenzi D, Carrea A, Izzi C, Casu D, Allegri L, Schmidt-Ott KM, Barasch J, Scolari F, Ravazzolo R, Ghiggeri GM, and Gharavi AG

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Chromosome Mapping, Female, Genetic Linkage, Genetic Markers, Genotype, Humans, Infant, Kidney pathology, Lod Score, Male, Middle Aged, Pedigree, Penetrance, Chromosomes, Human, Pair 1 genetics, Genes, Dominant physiology, Genetic Predisposition to Disease, Kidney abnormalities, Ureteral Diseases genetics
Abstract

Nonsyndromic defects in the urinary tract are the most common cause of end-stage renal failure in children and account for a significant proportion of adult nephropathy. The genetic basis of these disorders is not fully understood. We studied seven multiplex kindreds ascertained via an index case with a nonsyndromic solitary kidney or renal hypodysplasia. Systematic ultrasonographic screening revealed that many family members harbor malformations, such as solitary kidneys, hypodysplasia, or ureteric abnormalities (in a total of 29 affected individuals). A genomewide scan identified significant linkage to a 6.9-Mb segment on chromosome 1p32-33 under an autosomal dominant model with reduced penetrance (peak LOD score 3.5 at D1S2652 in the largest kindred). Altogether, three of the seven families showed positive LOD scores at this interval, demonstrating heterogeneity of the trait (peak HLOD 3.9, with 45% of families linked). The chromosome 1p32-33 interval contains 52 transcription units, and at least 23 of these are expressed at stage E12.5 in the murine ureteric bud and/or metanephric mesenchyme. These data show that autosomal dominant nonsyndromic renal hypodysplasia and associated urinary tract malformations are genetically heterogeneous and identify a locus for this common cause of human kidney failure.

Published
2007
Full Text
View/download PDF

16. Comparison between hemofiltration and hemodiafiltration in a long-term prospective cross-over study.

Author

Altieri P, Sorba G, Bolasco P, Ledebo I, Ganadu M, Ferrara R, Menneas A, Asproni E, Casu D, Passaghe M, Sau G, and Cadinu F

Subjects
Blood Pressure, Cross-Over Studies, Electric Impedance, Female, Humans, Kidney Failure, Chronic physiopathology, Kidney Failure, Chronic therapy, Male, Middle Aged, Hemodiafiltration, Hemofiltration
Abstract

Background: The objective of the study was to compare the convective treatment modes, on-line hemofiltration (HF) and on-line hemodiafiltration (HDF), regarding cardiovascular tolerance and effects on blood pressure, when applied under similar conditions in stable dialysis patients., Methods: 39 clinically stable dialysis patients were treated with HD for 6 months (run-in period), followed by HF and HDF in random order for 2x6 months. Similar biocompatibility (same membrane and fluid quality), similar treatment time and urea Kt/V were achieved using AK100/200 ULTRA machines, polyamide membranes in low-flux and high-flux versions and appropriate adjustment of blood flow rate (Qb) and dilution ratio (Qb/Qinf). Predilution was used for HDF (target dilution ratio = 2/1 ) as well as for HF (target dilution ratio = 1/1)., Results: 30 patients completed the study; 5 dropped out for non-study related reasons and 4 for non-compliance. Treatment with HF in comparison to HDF showed fewer hypotension episodes during the sessions per patient and month (HF: 0.5, HDF 1.1; p = 0.017), less plasma expander administration per patient and month (HF: 35.9 ml, HDF: 103.1 ml; p = 0.035), fewer episodes of intra-session headache (HF: 0.1, HDF: 0.4; p = 0.06), and higher pre-session MAP (HF: 98.4 mmHg, HDF: 93.8 mmHg; p = 0.037). No significant difference was found in inter-treatment weight gain, post-session MAP, or pre-session plasma sodium., Conclusions: HF and HDF provide good control of intra-session symptoms and blood pressure in stable patients. Treatment with HF resulted in a significant reduction in intra-session hypotension and a slight but significant increase in pre-session MAP, caused by an increase in systolic BP without any effect on the prevalence of hypertension or the dose of antihypertensive drugs, all compared to HDF.

Published
2004

17. Pre-dilution haemofiltration--the Sardinian multicentre studies: present and future. The Sardinian Collaborative Study Group on Haemofiltration On-Line.

Author

Altieri P, Sorba G, Bolasco P, Asproni E, Ledebo I, Boström M, Ferrara R, Ganadu M, Cossu M, Cadinu F, Cabiddu G, Serra G, Casu D, Bolasco F, Passaghe M, Ghisu T, Sau G, Ginanni A, Pistis R, Calvisi L, and Galfré A

Subjects
Adult, Aged, Cross-Over Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Renal Dialysis, Urea metabolism, Hemofiltration
Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results